Biohaven-2026-JPM.pdf

1、 2026 Biohaven,Ltd.All rights reserved.44th Annual J.P.Morgan Healthcare ConferenceJanuary 12,2026Vlad Coric,M.D.Chairman and Chief Executive OfficerCAMERONLiving with Graves DiseaseForward-Looking StatementThis presentation includes forward-looking statements within the meaning of the Private Secur

2、ities Litigation Reform Act of 1995,including statements about Biohaven Ltd.(the“Company”)and our planned and ongoing trials(including those for our taldefgrobep alfa,opakalim,BHV-2100,BHV-8000,BHV-1300,BHV-1400,BHV-1510 and BHV-1600 development programs),the timing of and the availability of data f

3、rom our clinical trials,the timing and our decisions to proceed with our planned regulatory filings,the timing of and our ability to obtain regulatory approvals for our product candidates,the clinical potential utility of our product candidates,alone and as compared to other existing potential treat

4、ment options,and the potential advancement of our early phase programs including BHV-1310,BHV-1530 and BHV-1500.The use of certain words,including“continue”,“plan”,“will”,“believe”,“may”,“expect”,“anticipate”and similar expressions,is intended to identify forward-looking statements.Investors are cau

5、tioned that any forward-looking statements,including statements regarding the future development,timing and potential marketing approval and commercialization of our development candidates are not guarantees of future performance or results and involve substantial risks and uncertainties.Actual resu

6、lts,developments and events may differ materially from those in the forward-looking statements as a result of various factors including:the expected timing,commencement and outcomes of Biohavens planned and ongoing clinical trials;the timing of planned interactions and filings with the Food and Drug